Key points are not available for this paper at this time.
Lymph node recurrence accounts for 12%–37% of ovarian cancer relapses. It is considered more indolent compared with parenchymal and peritoneal disease and more suited to take advantage of surgical rather than medical treatment.11 According to recent clinical trials, surgery has been confirmed
Russo et al. (2024) studied this question.